ELOX

Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. (ELOX) has 3 SEC Form 4 filings (6 transaction rows) in the rolling window, disclosed by 0 distinct insiders. Most recent filing: Jun 5, 2026.

  • Industry:Biotechnology
  • CEO:Sumit Aggarwal
  • Employees:18
  • HQ:Watertown, MA, US
  • IPO:1999-04-26

No open-market insider trades for ELOX (Eloxx Pharmaceuticals, Inc.) in the last 365 days.

Why this page may be quiet. Tracefour displays Form 4 open-market purchases (P) and sales (S): the two transaction codes that signal directional conviction. Restricted stock grants, option exercises, gifts, and tax-withholding sales are filed but intentionally not shown: they're disclosure mechanics, not buy/sell decisions.

Many large-cap executives trade through pre-scheduled 10b5-1 plans set months in advance and batch-disclosed each quarter, so the latest filing on EDGAR for a mega-cap can be weeks old without any insider actually choosing to trade in that window.

See all Form 4 filings on SEC EDGAR ↗

Related companies

Eloxx Pharmaceuticals, Inc. is in the Healthcare sector.